Erratum to: Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, doubleblind, placebo-controlled, crossover study

Article Corrected

Joseph Stauffer, Beatrice Setnik, Marta Sokolowska, et al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig 2009; 29 (12): 777–90

Corrections Made

Page 782: Drug Concentration Measurements section, last line, which previously read:

“The limits of quantification were 0.0003 µmol/L for morphine, 0.0104 nmol/L for naltrexone and 0.029 nmol/L for 6-β-naltrexol or 0.000725 nmol/L at the higher sensitivity working range.” has now been corrected as follows:

“The limits of quantification were 0.0007 µmol/L for morphine, 0.0104 nmol/L for naltrexone and 0.029 nmol/L for 6-β-naltrexol or 0.000725 nmol/L at the higher sensitivity working range.”

Page 787: Figure 5a, the markings on y-axis which previously read: 0, 0.05, 0.10, 0.15 Have now been corrected as follows: 0, 0.12, 0.23, 0.35, respectively.

Note

All online versions of this article have been updated to reflect these corrections.